Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Inventiva S.A.NASDAQ: IVA

Income Tax Expense · Q4 FY2025 · quarter ended Dec 2025

Income tax expense turns negative

Q4 FY2025 income tax expense was -€621.37K, compared with €194K a year earlier.

Context

  • Income tax expense amounted to 0.5% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€621.37K— QoQ
Last fiscal yearDec 2025
€22K-93.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-420.3%——
1 year-93.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
22K EUR
Year-over-year change
-93.0%
4-year CAGR
-50.4%

Income Tax Expense vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -93.0% is the 4th highest of 6, against a peer median of +47.0%.
  • Income tax expense amounts to 0.5% of revenue for IVA, versus a peer median of 0.1%.
IVA Competitors
Income Tax Expense for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$169K USD+47.0%+80.6%286.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$92K USD+103.7%—0.1%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$30.19K USD+7553.1%——
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
IVVDInvivyd, Inc.LTM Mar 2026$0 USD——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$550K USD-6011.1%—4.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$9.19M USD-3303.1%—517.9%
Peer median (excluding IVA) —+47.0%+80.6%0.1%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.